Dr
Helena
Grady

Trainee Patent Attorney

Nottingham Office York Office

Chemistry

Telephone. +44(0) 115 857 5000
Email. [email protected]

Experience

Helena graduated from the University of Bath in 2011 with an MChem (Hons) in Chemistry with Industrial Training. She completed her industrial training year at AstraZeneca as an Analytical Chemist.

After her degree, Helena joined the Bristol Centre for Functional Nanomaterials, an interdisciplinary doctoral training centre at the University of Bristol. Her PhD research involved the development and characterisation of novel antimicrobial nanomaterials for functionalising central venous catheters. Following her PhD, Helena worked as a Senior Development Scientist for a biopharma spin-out company from the University of Bristol, specialising in alternative antimicrobial technologies for medical, dental and veterinary applications.

Helena joined HGF as a Trainee Patent Attorney in August 2018, and works with clients to draft and prosecute patent applications across a wide range of chemical sciences, including the fields of pharmaceuticals, materials and medical devices.

Qualifications

Trainee


MCHEM

MChem in Chemistry with Industrial Training

PHD

PhD in Functional Nanomaterials

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate in Intellectual Property

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.